Comparison · NCT00102531-sae
Cisplatin Liposomal 24 mg/m2 vs Cisplatin Liposomal 36 mg/m2: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Cisplatin Liposomal 24 mg/m2 vs Cisplatin Liposomal 36 mg/m2: serious adverse events. Trial comparisons, record NCT00102531-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00102531-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.143 | 0.0257 | 0.513 | wilson | |
| Risk in group 2 | 0.167 | 0.047 | 0.448 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0238 | -0.329 | 0.365 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.857 | 0.0938 | 7.83 | log | |
| Odds ratio, group 1 over group 2 | 0.833 | 0.0616 | 11.3 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Cisplatin Liposomal 24 mg/m2 than on Cisplatin Liposomal 36 mg/m2 | 42 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Cisplatin Liposomal 24 mg/m2 | Inhaled liposomal cisplatin was administered over 1 day in a 14-day treatment cycle by inhalation for a maximum of 6 cycles.~Cisplatin liposomal | 1 | 7 | EG000 |
| Group 2 | Cisplatin Liposomal 36 mg/m2 | The study allowed for a dose escalation of liposomal cisplatin to 36 mg/m2 if no adverse events of Grade 3 or higher occurred after at least 3 cycles of drug administration at 24 mg/m2~Cisplatin liposomal | 2 | 12 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- AEs were followed until resolution until 30 days post last dose.
Source ClinicalTrials.gov
Trial
- Title
- Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung
- NCT number
- NCT00102531
- Phases
- PHASE1, PHASE2
- Conditions
- Osteosarcoma Metastatic
- Interventions
- Cisplatin liposomal
- Lead sponsor
- Insmed Incorporated
- Results first posted
- 2017-08-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00102531?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00102531-sae